Altimmune Inc Share Price Nasdaq
Equities
US02155H1014
Biotechnology & Medical Research
Sales 2024 * | 31.25M 2.61B | Sales 2025 * | 25M 2.09B | Capitalization | 433M 36.17B |
---|---|---|---|---|---|
Net income 2024 * | -59M -4.93B | Net income 2025 * | -142M -11.86B | EV / Sales 2024 * | 11.8 x |
Net cash position 2024 * | 63.88M 5.33B | Net cash position 2025 * | 257M 21.43B | EV / Sales 2025 * | 7.06 x |
P/E ratio 2024 * |
-7.26
x | P/E ratio 2025 * |
-4.85
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
Latest transcript on Altimmune Inc
Managers | Title | Age | Since |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 30/18/30 |
Director of Finance/CFO | 66 | 31/21/31 | |
Anthony Blandin
CMP | Compliance Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 01/10/01 |
Mack Gill
BRD | Director/Board Member | 72 | 01/04/01 |
Philip Hodges
BRD | Director/Board Member | 56 | 01/03/01 |
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |